Blocking of Interleukin-17 during Reactivation of Experimental Arthritis Prevents Joint Inflammation and Bone Erosion by Decreasing RANKL and Interleukin-1

This publication has 39 references indexed in Scilit:

• Treatment with a neutralizing anti‐murine interleukin‐17 antibody after the onset of collagen‐induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion
  Arthritis & Rheumatism, 2004
• Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro
  Annals of the Rheumatic Diseases, 2002
• Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin‐17 receptor IgG1 Fc fusion protein
  Arthritis & Rheumatism, 2002
• PATHWAYS BY WHICH INTERLEUKIN 17 INDUCES ARTICULAR CARTILAGE BREAKDOWN IN VITRO AND IN VIVO
  Cytokine, 2001
• The combination of tumor necrosis factor ? blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model
  Arthritis & Rheumatism, 2001
• IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1
  Journal of Biological Chemistry, 2001
• IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
  Journal of Clinical Investigation, 1999
• Progression of Articular Destruction and the Production of Tumour Necrosis Factor‐α in Antigen‐Induced Arthritis in Rabbits
  Scandinavian Journal of Immunology, 1997
• Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritis
  Arthritis & Rheumatism, 1995
• Flare-up reaction of streptococcal cell wall induced arthritis in Lewis and F344 rats: the role of T lymphocytes
  Clinical and Experimental Immunology, 1990